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Antenatal vaccination has become a part of routine care during pregnancy in the UK and 
worldwide, leading to improvements in health for both pregnant women and their infants. 
However, uptake remains sub-optimal. Other antenatal vaccines targeting major neonatal 
pathogens, such as Group B streptococcus (GBS), the commonest cause of sepsis and 
meningitis in the neonatal period, are undergoing clinical trials but more information is 
needed on how to improve acceptance of such vaccines.  
METHODS 
Qualitative study using focus groups and interviews; involving 14 pregnant women, 8 
mothers with experience of GBS, and 28 maternity healthcare professionals. Questions were 
asked regarding antenatal vaccines, knowledge of GBS, attitudes to a potential future GBS 
vaccine and participation in antenatal vaccine trials.  
RESULTS  
All participants were very cautious about vaccination during pregnancy, with harm to the 
baby being a major concern. Despite this, the pregnant women and parents with experience of 
GBS were open to the idea of an antenatal GBS vaccine and participating in research, while 
the maternity professionals were less positive. Major barriers identified included lack of 
knowledge about GBS and the reluctance of maternity professionals to be involved. 
INTERPRETATION 
In order for a future GBS vaccine to be acceptable to both pregnant women and the 
healthcare professionals advising them, a major awareness campaign would be required with 
significant focus on convincing and training maternity professionals.  
KEYWORDS 
Group B streptococcus, antenatal vaccine, pregnancy, attitudes, healthcare professionals, 
pregnant women, clinical trials 
  
INTRODUCTION 
Group B streptococcus (GBS, also known as Streptococcus agalactiae) is the commonest 
cause of sepsis and meningitis in the first three months of life (1-4). The incidence appears to 
be increasing (3, 4) and mortality is around 10%, with about half of babies who recover from 
GBS meningitis left with long term neurodevelopmental sequelae (5).  
Around 14-30% of UK women carry GBS in their gastrointestinal or genital tract (6-8) and 
without prophylaxis around 1% of babies born to these women will develop invasive GBS 
infection (6-8). The majority of early-onset infections (occurring from 0-6 days of life) can be 
prevented by administration of intravenous Benzylpenicillin to the mother during labour (9, 
10), but this does not prevent the less common late-onset disease (7-90 days of life) (10, 11) 
and a major challenge is identifying which women should receive these intrapartum 
antibiotics. The UK currently uses a risk-based approach in which women with known risk-
factors are given antibiotics but are not tested for GBS carriage (12). This differs from the 
USA, Australia and many European countries where women are predominantly offered 
screening for GBS during the later stages of pregnancy and are given antibiotics during 
labour if their test is positive (13, 14).  
Neither strategy is ideal. The risk-based approach may miss a significant proportion of 
colonised women (7, 15, 16) and since its introduction, GBS rates in the UK have continued 
to rise (3), while countries adopting a screening policy have seen a significant fall (11). 
However, screening programs also face multiple issues including sub-optimal uptake, and 
potentially greater antibiotic use (4, 17). Neither strategy impacts on prenatal or late-onset 
infection. 
Therefore, the prospect of an antenatal vaccine, which could be given to all women during 
pregnancy and would likely protect against both prenatal, early- and late-onset disease, is an 
attractive option. At present there is no licenced GBS vaccine; however, clinical trials have 
shown promising initial results (18) and larger scale studies are ongoing (NCT02459262).  
One potential challenge facing the introduction of a GBS antenatal vaccine is that in order for 
a vaccine to be effective, it must be accepted by both the target population, namely pregnant 
women, and the healthcare professionals caring for them. In the UK, two antenatal vaccines 
are recommended; influenza and pertussis (19). However, despite the increasing level of 
evidence that these vaccines are both safe and effective (20, 21), uptake rates remain low – 
approximately  60% for pertussis (22) and only 38.3% for influenza (23).  
This qualitative study was conducted as part of a larger project with the overall aim of 
obtaining more in-depth information on the attitudes and opinions of pregnant women and 
healthcare professionals towards antenatal vaccination, GBS, a potential GBS vaccine and 
participation in clinical trials during pregnancy, which were prominent issues raised during 
an initial large-scale survey of British women of child-bearing age (24, 25).  
 
METHODS 
This qualitative study was conducted in Spring 2014 and approved by the NRES ethics 
committee South Central- Hampshire A (Ref 13/SC/0619).  
Participants 
There were three categories of participant; 14 pregnant women, 8 women with experience of 
their own child being affected by GBS infection and 28 maternity professionals (10 midwives 
and 18 obstetric doctors). Further details are given in tables 1 and 2.  
Pregnant women were recruited using participant information booklets/invitations sent with 
their ultrasound appointment letter. These appointment letters are sent to all pregnant women 
upon informing their GP/midwife of their pregnancy. Maternity professionals were recruited 
through adverts at educational meetings, on staff newsletters and in staffrooms. Of note, all 
participants and maternity staff were receiving antenatal care/working within the publically 
funded UK National Health Service. This is typical for antenatal care in the UK where only 
0.4% of women receive exclusively private maternity care (26). The recruitment area (Oxford 
University Hospital NHS Trust) includes all levels of maternity care from community home 
birth services to a high-risk regional referral unit.  Parents who previously had a child with 
GBS infection responded to an advert in the Group B Strep Support newsletter. All 
participants were offered a £20 shopping voucher to compensate for their time.  
Inclusion criteria were that all participants were over 18 years of age, able to speak and 
understand English, able to give informed, written consent and lived within one-hour travel 
distance or were able to travel themselves to the study site (Oxford, UK). All parents in the 
GBS experienced group had a child affected by GBS infection. Maternity professionals were 
required to be midwives or obstetric doctors currently working within the Oxford University 
Hospitals NHS Trust. Participation was voluntary and participants were allowed to withdraw 
at any point without giving a reason. 
Due to the sensitive nature of their previous experience, women with experience of GBS took 
part in individual interviews only, while pregnant women were allocated, based on their 
availability, to take part in either interviews or focus groups. A decision was made to conduct 
focus groups only amongst the maternity professionals to reflect the normal working 
environment in which views and practice are influenced by discussion with colleagues and 
hospital or national policy. To avoid any sense of inter-professional hierarchy, focus groups 
contained participants of the same discipline (e.g. either midwives, or obstetric doctors).  
Interviews and focus groups topic guides 
Topic guides for both the interviews and focus groups were developed after a review of the 
literature, and using data and themes obtained from a previous online survey (24, 25). As 
previous research had shown a general low level of knowledge about GBS (24),  a GBS fact 
sheet was provided during the interviews/focus groups with details on incidence, mortality, 
screening and current status of a GBS vaccine. 
The topic guides were piloted in two interviews (one with a pregnant women and one with a 
GBS experienced parent) and minor adjustments were made based on the feedback obtained.  
Conduct of the interviews/focus groups 
Informed, written consent was obtained before the start of each interview or focus group. All 
interviews were conducted face-to-face by a qualitative researcher, in either their own home 
or at the study site. Focus groups took place at either the study site offices or the hospital (for 
maternity professionals) and were led by the same researcher with a clinical member of the 
study team in order to clarify technical questions raised by the group. All interviews and 
focus groups were audio recorded. 
Analysis 
All recordings were transcribed verbatim and a thematic framework analysis was conducted 
using NVIVO 10 software, structured around the main areas of questioning. Data analysis 
and data collection proceeded iteratively and early findings informed questioning in the 
subsequent interviews and focus groups until theoretical saturation was felt to be achieved. 
The content of focus group discussions was similarly analysed by theme, but with additional 
analysis of the interactions between focus group members in each case, and how this affected 
the content. Where relevant we report these interactive aspects in the findings. 
 
RESULTS 
General attitudes towards vaccines 
A range of views were expressed regarding vaccinations, with most women focussing on the 
context of childhood vaccination. Some were strongly supportive; 
“I think it’s a brilliant idea and I think you’d be mad not to do it to be honest.” (Pregnant 
women 0002) 
 While others were more hesitant,  
“I’m like ambivalent, so I, I would prefer to live in a world where we don’t need vaccines.” 
(Pregnant women 0012) 
However, the overarching theme was a general acceptance of childhood vaccines, as this was 
perceived as the norm and the majority of childhood vaccines had been around for a long 
time. Key influences included the attitudes of the women’s own parents towards vaccination, 
and the perceived risk-benefit ratio with the severity of the condition being more important 
than how common it was. There was general perception that vaccines themselves may carry a 
risk, some women spoke about the MMR-Autism debate or media concerns about the Swine 
flu vaccine, nevertheless, the risk of not having the vaccine was often felt to be greater.  
Vaccination during pregnancy 
In contrast to routine childhood vaccination, pregnant women were much more cautious 
about receiving vaccines while pregnant, with a major concern being potential harm to their 
baby. 
“I guess it’s a little bit more scary, so it’s sort of fair enough when you’ve got to have your 
own vaccine as an adult because, you kind of, are making that choice.... But I guess it’s a 
little bit more of an unknown when you’re pregnant because you do worry about is it going to 
affect the baby in a negative way.” (Pregnant woman 0002) 
Despite these anxieties, many of the women interviewed had received the flu vaccine and/or 
intended to have the pertussis vaccine, the main influence being a recommendation either 
nationally or from a healthcare provider. Some expressed specific worries about the influenza 
vaccine being recommended in the first trimester, advice which had changed since previous 
pregnancies, and commented that they would prefer to have it later as this was perceived as 
safer and at this point the symptoms of early pregnancy would have resolved.  
The concept of the vaccines being introduced as a result of scientific research was mentioned 
by a number of women, though few had considered the specifics of this research, such as the 
size of the clinical trials or length of follow up, and assumed that vaccines were being 
recommended based on good evidence. Midwives and other healthcare professionals were 
viewed as important sources of reliable information, though many would also discuss with 
their partner and pregnant friends.  
The midwives and obstetric doctors also echoed the pregnant women’s cautious attitude 
towards vaccination during pregnancy and commented on the challenge of practice changing 
recently, from advising no medications or vaccines during pregnancy to promoting antenatal 
vaccination. Several raised concerns about the number of vaccines, “the cocktail”, now 
recommended and the possibility of long term effects. In keeping with this, some wanted 
clinical trials to follow-up outcomes for 15-20 years or even two generations. The existence 
of a national recommendation was key for them and, while they also spoke about the 
important of research, many had not looked into the details themselves and, in a similar way 
to the pregnant women, trusted in the ‘official’, ‘NHS’ guidance.  
Awareness of GBS and attitudes towards a GBS vaccine 
Awareness of GBS in the pregnant women group was low. Both the pregnant women and the 
GBS experienced group felt that large-scale awareness campaigns, similar to those targeting 
meningococcal disease, were needed. The word ‘meningitis’ was felt to resonate strongly 
with the general population and if people were aware that GBS could cause meningitis this 
would indicate it was a dangerous condition. Those with experience of GBS were particularly 
keen that information was given early in pregnancy, as they had not received it themselves. 
The pregnant women were generally supportive of a GBS vaccine, particularly after receiving 
additional information about GBS, with the potential mortality being a key factor. 
Unsurprisingly, the GBS experienced group were strongly in favour of a vaccine. Offering 
the vaccine to all pregnant women rather than using a screening approach was seen as a 
positive aspect for both of these groups,  
“It’s a lot neater being given a vaccine and it’s less open to error in terms of how it’s 
administered because at the moment the NICE guidelines are very complicated and medical 
professionals don’t understand them and people fall through the gaps like I did.” (GBS 
experienced group 1009) 
The majority of pregnant women felt they would want to know more facts about the vaccine 
and GBS in general, for which midwives were considered to be the authoritative source of 
information. Those with experience of GBS also highlighted the need for better information, 
but in their experience, maternity staff and GPs were often not very well informed. 
In contrast, the midwives in the first focus group were less positive about a potential GBS 
vaccine, with cost-effectiveness and the safety of the vaccine being major concerns given the 
relatively few deaths from GBS in the UK. Some felt that screening would be more in 
keeping with the ‘natural’ approach favoured by midwifery culture,  
‘I suppose as a midwife my heart is more for screening than putting something into women 
that they don’t need to have. I want to try to pick up a really good screening tool’.  
(Midwife, focus group 1) 
One midwife, who had personal experience of looking after a mother whose baby had died of 
GBS, consistently tried to challenge this view, however, the other participants remained 
unconvinced and viewed her story as a one-off case. Nevertheless there was a discussion 
about keeping an open-mind. The midwives in the second focus group, one of whom had 
experienced cases of babies dying from GBS in her clinical practice, were more in favour of a 
vaccine. The obstetric doctors were also more willing to consider a GBS vaccine and argued 
that vaccination could be more cost-effective than treating the consequences of GBS 
infection. 
Participation in GBS vaccine research 
Many of the pregnant women were open to the idea of participating in clinical trials of 
vaccine research but were generally very cautious, felt they would need more information and 
would be less likely to take part if it were their first pregnancy.  
“I suppose I’d want to know more about it at that stage then, you know, I would want more 
than a leaflet I think, if I was actually going to take part in a trial.” 
(Pregnant woman 002) 
The GBS experienced group were very positive about research.  
“If I was going to fall pregnant again I would, I would volunteer. I would probably give you 
my arm now so you could happily give it (the GBS vaccine) to me. I would be more than 
happy to because I know the consequences” 
(GBS experienced group 1008) 
 Suggested methods of encouraging pregnant women to take part are listed in table 3. While 
travel and childcare expenses were seen as essential, a monetary payment for taking part was 
not felt to be a strong motivator by the pregnant women. The concept of being part of a 
control group, who did not receive the vaccine, was attractive to some, as they could 
contribute to the research without feeling they were putting their baby at risk. 
The maternity professionals groups were less keen on being involved and while some might 
consider distributing information about the trial, they would not want to be seen to be 
recommending it unless they could be convinced of the vaccine safety. They acknowledged 
that this ambivalence could be a major obstacle to recruitment. In contrast to the cautiously 
positive responses from the pregnant women, the second obstetric doctors’ focus group 




These data provide interesting insight into the attitudes of pregnant women, women with 
experience of GBS and maternity professionals, regarding antenatal vaccination. Overall, 
pregnant women and maternity professionals were typically cautious but accepting of the 
current recommended antenatal vaccines. Pregnant women and those with experience of GBS 
were generally supportive of a possible GBS vaccine and participating in research while the 
maternity professionals were more sceptical, with the notable exception of those who had 
direct experience of GBS.  There was a clear difference in attitudes between childhood 
vaccinations and vaccines offered during pregnancy. Childhood vaccinations were perceived 
as the default option and even vaccine-hesitant parents had decided to have their children 
vaccinated. A key factor in this seemed to be the perceived length of time these vaccines had 
been in use and pregnant women were able to reference their own experiences as children and 
the influence of their own parents on their decisions to vaccinate. On the other hand, the 
introduction of antenatal vaccination in the UK, initially with vaccination against swine flu, 
then seasonal influenza in 2010 followed by pertussis in 2012 (19), came on the background 
of a strong prevailing culture that no unnecessary medications should be given during 
pregnancy and this seemed to strongly influence both the pregnant women and maternity 
professionals. This may change and evolve with time - in many developing countries, 
maternal immunization to prevent neonatal tetanus has been ongoing for many years and 
coverage rates are significantly higher, reaching 80-90%, in some countries (27, 28).  
Although both pregnant women and midwives expressed concerns, it is important to note that 
women were engaged in working out how to fulfil a socially expected role of ‘good 
motherhood’, in which the focus is not just on them but also on their responsibility to protect 
their unborn child. For women, risk may be primarily perceived at a personal level – if your 
baby gets GBS, population statistics may feel irrelevant and almost any strategy to avoid 
potential major harm may seem desirable. There was some evidence in women’s accounts of 
a general sense of pressure to do or not do things in pregnancy without really understanding 
why. This could be considered a manifestation of ‘reproductive citizenship’, whereby 
pregnant women and their fetuses become ‘potent focal points for regulation, monitoring and 
control’ (29) and the fetus ‘is privileged over the pregnant woman….eclipsing the maternal 
body in which it grows’ (29). However, in the specific case of GBS and a GBS vaccine, 
women in our sample presented this in more proactive terms of their own agency, wanting to 
be informed about how to protect their baby, and thereby protect themselves from the grief of 
neonatal loss, and seeing it as a positive opportunity rather than irksome surveillance or 
control. This may be at odds with midwives’ perception of GBS as a very small collective 
risk, informed by professional norms of pregnancy as a safe, normal and healthy process. 
Thus women’s threshold for weighing up the risk/benefit ratio comes from a very different 
perspective. It is significant that the midwives who themselves had encountered GBS in their 
own practice saw risk through a similar lens as the women. 
Providing information about both the vaccines and the diseases they prevent has been shown 
to be key (30) and this was echoed by all groups in this study. Pregnant women looked to 
their healthcare professionals, particularly midwives, for advice; however, the healthcare 
professionals often echoed their concerns, despite the increasing evidence that antenatal 
vaccination is both safe and effective (20, 21, 31, 32). However, some of the healthcare 
workers who had received additional vaccine-related training were more positive and keen to 
educate their colleagues. Addressing the ideas and concerns about antenatal vaccination 
amongst maternity professionals could therefore be key in promoting antenatal vaccine 
uptake.  
Encouragingly, pregnant women and the GBS experienced group were generally in favour of 
GBS vaccine. They highlighted comparable ideas and concerns to those expressed in a 
similar qualitative study conducted in Canada (33). However, an important difference is that 
GBS screening is routine in Canada and interestingly, the healthcare professionals, with their 
experience of screening, were very much in favour of vaccination as an alternative. This 
contrasts with the views expressed by many of the professionals participating in this study, 
some of whom preferred the possibility of a screening approach. Our data also suggest that 
while the target population of pregnant women may be open to the idea of taking part in 
clinical trials, a major obstacle could be the attitudes of the healthcare professionals and 
significant work must be undertaken to persuade this key group. In the maternity 
professionals’ focus groups, the influence of collective professional norms was strongly in 
evidence, with any dissenting voices, such as the midwife with experiences of GBS, being 
regarded as less relevant by the others.  
Qualitative studies are designed to elicit a range of perspectives, rather than to be statistically 
representative, so while we have uncovered important themes to consider, if a vaccine is to be 
implemented effectively, we cannot conclude how common these attitudes and concerns are 
in the whole patient or professional population. We also cannot determine whether those 
volunteering to participate truly represent the population of interest, however our recruitment 
methods aimed to give as wide a range as possible the opportunity to take part. Focus groups 
were selected because they reflect the reality of how professional staff culture works and how 
women form views about topics in pregnancy. However, a limitation of focus groups is that 
participants may have felt obligated to go along with the current hospital/national policies 
and despite the attempts to minimise the effects of hierarchy, more junior members of the 
group may have felt less able to contribute. Conducting individual interviews may have 
removed some of these barriers, but would have been less effective in examining how 
decisions and consensus are reached in the workplace setting. As Kitzinger (34) argues, much 
of what we learn in life is acquired by talking and observing in groups; if we want to explore 
people’s understandings, ‘it makes sense to employ methods which actively encourage 
examination of these social processes in action’.  
With these limitations in mind, the depth of responses and emerging themes from this study 
have aided the development of a questionnaire, which has since been used for a large scale 
national survey of pregnant women and healthcare workers (35). Altogether, this project 
identified key issues which need to be addressed and potential strategies which can help 
prepare the UK for an effective GBS vaccine. 
 
   
Table 1: Pregnant women and women with experience of GBS 
 
Group Number of 
participants 
Age range Participant characteristics 
Pregnant 
women 
14 21-41 years  First pregnancy: 5 
 Second pregnancy: 7 
 Third pregnancy: 1 





8 25-45 years  1 child affected: 6 
 2 children affected: 2 
 
 Child alive and well: 5 
 Child died: 4 
 Child with ongoing           
problems due to GBS: 1 
 
  







Participant characteristics (including any 
additional information specified by participant) 
1 9  All midwives 
 Additional specified roles: 4 research 
midwives, 1 midwife/sonographer, 1 
community/research midwife 
2 2  Both community midwives 
 1 trains other midwives about influenza 
vaccine 
3 10  Obstetric doctors 
4 7  Obstetric doctors, one consultant, remainder 
in obstetric training posts 
  
Table 3: Suggested methods for encouraging participation in GBS vaccine trials 
 
 




Offer opportunity to speak with a parent 
affected by GBS (not all would want this) 
Offer extra ultrasound scans 
Invited to take part by their own midwife Offer opportunity to speak with a parent 
affected by GBS 
Enthusiasm and support from their own 
midwife 
Midwives to be involved in recruitment 
(obstetric doctor group only) 
Extra appointments/attention Using patient advocates (e.g. GBS 
experienced parents) to promote the trial to 
maternity professionals 
Flexible evening and weekend appointments Possible financial incentive/free nappies 
An emphasis on protection for their own 
baby 
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